Compare AQMS & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AQMS | ITRM |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9M | 24.3M |
| IPO Year | 2015 | 2018 |
| Metric | AQMS | ITRM |
|---|---|---|
| Price | $5.41 | $0.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | $9.00 |
| AVG Volume (30 Days) | 135.5K | ★ 731.7K |
| Earning Date | 11-12-2025 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $390,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $550.00 | $325.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.37 | $0.36 |
| 52 Week High | $39.40 | $2.10 |
| Indicator | AQMS | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 38.29 | 33.37 |
| Support Level | $5.96 | $0.44 |
| Resistance Level | $7.61 | $0.49 |
| Average True Range (ATR) | 0.55 | 0.04 |
| MACD | -0.17 | 0.00 |
| Stochastic Oscillator | 3.19 | 3.75 |
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.